BIO-KOREA
13.5.2020 06:36:05 CEST | Business Wire | Press release
The BIO KOREA Organizing Committee announced it will hold the BIO KOREA 2020 International Convention scheduled for May 18–23 as an online convention instead of an in-person event for this year.
The decision was based on the impact of COVID-19, the safety of the attendees and global health recommendations regarding large, in-person gatherings.
BIO KOREA 2020 Online Convention
- Date: May 18 09:00 to 23 18:00 (KST)
- Point of Access: www.biokorea.org
- Program: Online Business Forum with Partnering, Virtual Exhibition, e-Conference, Invest Fair, Job Fair
Online Business Forum with Partnering
BIO KOREA 2020 Online Convention will focus on the virtual collaboration with its Partnering system allowing attendees to schedule virtual meetings to maximize their business development and licensing potential. International participation continues to grow. Numerous companies from 20+ countries are already joined and expected to showcase their advanced technologies at BIO KOREA 2020.
Definitely expecting to be a place where various kinds of discussion will be held, with Korean companies as not just the companies which are leading bio industry in Korea such as LG Chem Life Science, Samsung Biologics, Celltrion, and Hanmi Pharmaceuticals, etc., also promising SMEs like Organoid Science, YBRAIN, and Amyloid Solution are attending to foster their business. And 24-hour meeting slots will let strengthen your digital network across time zones.
Virtual Exhibition
The new format includes Virtual Exhibition where has set to show the cutting-edge technologies and products of exhibitors in various ways such as Digital Scan, Animation, 360° VR, and so on. 350+ exhibitors, from start-up to the global enterprise, will be at BIO KOREA's virtual exhibition and also there will be COVID-19 Special Zone to introduce South Korea's effective diagnostic tests, high-tech medical technology, and protocols.
e-Conference
The conference of BIO KOREA will also come with the online format under the theme of “A New Paradigm in the Age of Data Science” including expert-level content focused on the most pressing industry topics including COVID-19, Vaccine, Alzheimer’s Disease, Electroceutical, Digital Pathology, Digital Therapeutics, AI (Artificial Intelligence). BIO KOREA 2020’s e-Conference, covering 13 topics with 90+ speakers, will bring the most up-to-date conversations in biopharma to your home office.
Invest Fair
Invest Fair is an event where pharmaceuticals, bio, and healthcare companies that are advancing into the global market and developing new drugs introduce their superior technology and investors to the companies’ vision and strategy. Along with online hosting, it maintains its attendance by impressive lineups of 24 companies such as GC Greencross, Celltrion, Tium BIO, and ABL Bio.
Job Fair
Aiming to place its main objective in recruiting talented individuals amongst undergraduates and postgraduates searching for job vacancies in bio industry, companies participating in Job Fair will share their success tips in various fields. Amid current bleak jobs pictures, about 30 companies are attending with 150+ job openings.
Lastly, BIO KOREA remains committed to amplifying the industry’s efforts to develop solutions for patients. In response to the COVID-19 pandemic, the special sessions dealing with its diagnostic kits, therapeutics and vaccines, also sharing the cooperation among the governments, industries are prepared. Jerom Kim from IVI will deliver the Keynote speech for the COVID-19 special session.
For more information, visit BIO KOREA’s Official Website: www.biokorea.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005997/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 17:32:00 CET | Press release
White s.r.o., exclusive owner of the VELOCIFERO brand, takes action in China to protect its intellectual property rights. Initial measures in Chongqing and Taizhou have already resulted in the seizure of vehicles alleged to be counterfeit. VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware
LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 16:53:00 CET | Press release
CapitalG leads Series C funding round at a $3B valuation to advance LangChain's agent engineering platform LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and
Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 13:00:00 CET | Press release
Maestro delivers concurrent planning on a single platform across discrete, process, consumer packaged goods and life sciences Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurr
SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 12:30:00 CET | Press release
Companies to co-develop six medical AI solutions targeting revenue expansion and cost reduction; SBC Medical secures priority sales rights in Japan and South Korea and targets B2B expansion across Asia SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,
SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 12:30:00 CET | Press release
Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom